Detalhe da pesquisa
1.
AZD1480: a phase I study of a novel JAK2 inhibitor in solid tumors.
Oncologist
; 18(7): 819-20, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23847256
2.
Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.
J Clin Oncol
; 23(31): 8081-92, 2005 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-16204011
3.
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.
J Clin Oncol
; 22(5): 785-94, 2004 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-14990633
4.
DCE-MRI assessment of the effect of vandetanib on tumor vasculature in patients with advanced colorectal cancer and liver metastases: a randomized phase I study.
J Angiogenes Res
; 1: 5, 2009 Sep 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-19946413
5.
Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer.
J Clin Oncol
; 26(33): 5407-15, 2008 Nov 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-18936474